Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Acalabrutinib Treatment in Very Old (≥80y) and/or Frail Patients with Chronic Lymphocytic Leukemia (CLL) - Primary Endpoint Analysis of the Phase II CLL-Frail Trial

Blood (2024) 144 (Supplement 1): 4618.

https://doi.org/10.1182/blood-2024-200848

Published: 2024

Journal Articles

Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple Myeloma

Blood (2022) 140 (Supplement 1): 287–288.

https://doi.org/10.1182/blood-2022-159357

Published: 2022

Journal Articles

A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Idelalisib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Nadine Kutsch, MD, Christian Pallasch, Thomas Decker, Holger Hebart, Kai Uwe Chow, Ullrich Graeven, Jens Kisro, Alexander Kroeber, Eugen Tausch, Clemens-Martin Wendtner, Michael J. Eckart, Stephan Stilgenbauer, Xi Huang, Juliane M. Jürgensmeier, Pankaj Bhargava, Michael Hallek, Barbara F. Eichhorst, MD

Blood (2019) 134 (Supplement_1): 3047.

https://doi.org/10.1182/blood-2019-131025

Published: 2019

Journal Articles

Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy

Blood (2018) 132 (7): 694–706.

https://doi.org/10.1182/blood-2017-10-810739

Published: 2018

Includes: Supplemental data

Journal Articles

JAK2-Inhibitor Therapy Associated Lymphomas in Myelofibrosis: Distinct Clinico-Pathological Features Recapitulated in a Mouse Model

Blood (2017) 130 (Supplement 1): 1643.

https://doi.org/10.1182/blood.V130.Suppl_1.1643.1643

Published: 2017

Journal Articles

Lenalidomide with Low-Dose Dexamethasone (Rd) Continuously Versus Rd Induction, Tandem MEL140 with Autologous Transplantation and Lenalidomide Maintenance: Planned Interim Analysis of a Prospective Randomized Trial in Patients 60-75 Years of Age with Multiple Myeloma

Blood (2014) 124 (21): 3969.

https://doi.org/10.1182/blood.V124.21.3969.3969

Published: 2014

Journal Articles

Bortezomib and Low-Dose Dexamethasone with or without Continuous Low-Dose Oral Cyclophosphamide for Primary Refractory or Relapsed Multiple Myeloma: Final Results of a National Multicenter Randomized Controlled Phase III Study

Martin Kropff, MD, Martin Vogel, MD PhD, Andrea Kreter, Dipl. Stat., Rudolf Schlag, Lothar Müller, MD, Rudolf Weide, MD, Wolfgang Knauf, MD PhD, Thomas Decker, MD, Heinrich Fiechtner, PhD, Georgi Kojouharoff, MD, Stephan Kremers, MD, Wolfgang E Berdel, MD

Blood (2014) 124 (21): 3470.

https://doi.org/10.1182/blood.V124.21.3470.3470

Published: 2014

Journal Articles

Prospective Randomized Trial of Len/Dex Induction Followed by Tandem MEL140 with Autologous Blood Stem Cell Transplantation and Len Maintenance Versus Continued Therapy with Len/Dex in Myeloma Patients Age 60–75 Years: Protocol-Defined Safety Analysis After 100 Patients

Blood (2012) 120 (21): 2012.

https://doi.org/10.1182/blood.V120.21.2012.2012

Published: 2012

Journal Articles

Recruitment of PKC-Beta to Lipid Rafts Mediates Apoptosis-Resistance in Chronic Lymphocytic Leukemia Expressing Zap-70.

Ingo Ringshausen, Michaela Wagner, Gloria Lutzny, Madlen Oelsner, Yvonne Feuerstacke, Thomas Decker, Christian Bogner, Christian Peschel, MD, Christian Meyer zum Buschenfelde

Blood (2009) 114 (22): 2354.

https://doi.org/10.1182/blood.V114.22.2354.2354

Published: 2009

Journal Articles

Bryostatin Enhances the Cytotoxic Effects of Anti-CD22 Immunotoxins in CLL by Two Distinct Mechanisms: Implications for a Sequential Therapy.

Ingo Ringshausen, Thomas Decker, Viola Biberacher, Christian Meyer zum Buschenfelde, Madlen Oelsner, Michaela Wagner, Christian Bogner, Christian Peschel, MD

Blood (2009) 114 (22): 3429.

https://doi.org/10.1182/blood.V114.22.3429.3429

Published: 2009

Journal Articles

Inhibition of Protein Kinase C (PKC) delta with Rottlerin Induces Apoptosis in B-CLL Cells, Augments Chemotherapeutic Cytotoxicity and Inhibits Antiapoptotic Survival Signals.

Ingo Ringshausen, MD, Kathrin Weick, Madlene Oelsner, Christian Peschel, MD, Thomas Decker, MD

Blood (2004) 104 (11): 2800.

https://doi.org/10.1182/blood.V104.11.2800.2800

Published: 2004

Journal Articles

BL22, a Recombinant Anti-CD22 Immunotoxin, Induces Cell Cycle Arrest and Apoptosis in B-Cell Lymphoma.

Thomas Decker, M.D., Michaela Wagner, Madlene Oelsner, Robert J. Kreitman, M.D., Ira Pastan, M.D., Christian Peschel, M.D., Thomas Licht, M.D.

Blood (2004) 104 (11): 4613.

https://doi.org/10.1182/blood.V104.11.4613.4613

Published: 2004

Journal Articles

MTOR (Mammalian Target of Rapamycin) Inhibition with RAD001 Induces Cell Cycle Arrest in Diffuse Large B Cell Lymphoma (DLBCL) Cells and Sensitizes DLBCL Cells to Rituximab Therapy.

Kathrin Wanner, Susanne Hipp, Christian Peschel, MD, Thomas Decker, MD

Blood (2004) 104 (11): 4620.

https://doi.org/10.1182/blood.V104.11.4620.4620

Published: 2004

Journal Articles

Induction of Apoptosis and Cell Cycle Arrest in Acute Myeloid Leukemia Cells by Histone Deacetylase Inhibitor, Suberoyl Hydroxamic Acid (SAHA): Lack of Cross-Resistance to Cytosine Arabinoside and Etoposide.

Sabine Dreyer, Thomas Decker, M.D., Michaela Wagner, Christian Peschel, M.D., Thomas Licht, M.D.

Blood (2004) 104 (11): 4362.

https://doi.org/10.1182/blood.V104.11.4362.4362

Published: 2004

Journal Articles

Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins

Thomas Decker, Madlene Oelsner, Robert J. Kreitman, Giuliana Salvatore, Qing-cheng Wang, Ira Pastan, Christian Peschel, Thomas Licht

Blood (2004) 103 (7): 2718–2726.

https://doi.org/10.1182/blood-2003-04-1317

Published: 2004

Journal Articles

Rapamycin-induced G 1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin

Thomas Decker, Susanne Hipp, Ingo Ringshausen, Christian Bogner, Madlene Oelsner, Folker Schneller, Christian Peschel

Blood (2003) 101 (1): 278–285.

https://doi.org/10.1182/blood-2002-01-0189

Published: 2003

Journal Articles

Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cδ

Ingo Ringshausen, Folker Schneller, Christian Bogner, Susanne Hipp, Justus Duyster, Christian Peschel, Thomas Decker

Blood (2002) 100 (10): 3741–3748.

https://doi.org/10.1182/blood-2002-02-0539

Published: 2002

Journal Articles

Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides

Thomas Decker, Susanne Hipp, Robert J. Kreitman, Ira Pastan, Christian Peschel, Thomas Licht

Blood (2002) 99 (4): 1320–1326.

https://doi.org/10.1182/blood.V99.4.1320.h8001320_1320_1326

Published: 2002

Journal Articles

Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells

Thomas Decker, Folker Schneller, Tim Sparwasser, Theresa Tretter, Grayson B. Lipford, Hermann Wagner, Christian Peschel

Blood (2000) 95 (3): 999–1006.

https://doi.org/10.1182/blood.V95.3.999.003k10_999_1006

Published: 2000

NARROW

Efficacy and Safety of Acalabrutinib Treatment in Very Old (≥80y) and/or Frail Patients with Chronic Lymphocytic Leukemia (CLL) - Primary Endpoint Analysis of the Phase II CLL-Frail Trial

A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Idelalisib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy

JAK2-Inhibitor Therapy Associated Lymphomas in Myelofibrosis: Distinct Clinico-Pathological Features Recapitulated in a Mouse Model

Lenalidomide with Low-Dose Dexamethasone (Rd) Continuously Versus Rd Induction, Tandem MEL140 with Autologous Transplantation and Lenalidomide Maintenance: Planned Interim Analysis of a Prospective Randomized Trial in Patients 60-75 Years of Age with Multiple Myeloma

Bortezomib and Low-Dose Dexamethasone with or without Continuous Low-Dose Oral Cyclophosphamide for Primary Refractory or Relapsed Multiple Myeloma: Final Results of a National Multicenter Randomized Controlled Phase III Study

Prospective Randomized Trial of Len/Dex Induction Followed by Tandem MEL140 with Autologous Blood Stem Cell Transplantation and Len Maintenance Versus Continued Therapy with Len/Dex in Myeloma Patients Age 60–75 Years: Protocol-Defined Safety Analysis After 100 Patients

Recruitment of PKC-Beta to Lipid Rafts Mediates Apoptosis-Resistance in Chronic Lymphocytic Leukemia Expressing Zap-70.

Bryostatin Enhances the Cytotoxic Effects of Anti-CD22 Immunotoxins in CLL by Two Distinct Mechanisms: Implications for a Sequential Therapy.

Inhibition of Protein Kinase C (PKC) delta with Rottlerin Induces Apoptosis in B-CLL Cells, Augments Chemotherapeutic Cytotoxicity and Inhibits Antiapoptotic Survival Signals.

BL22, a Recombinant Anti-CD22 Immunotoxin, Induces Cell Cycle Arrest and Apoptosis in B-Cell Lymphoma.

MTOR (Mammalian Target of Rapamycin) Inhibition with RAD001 Induces Cell Cycle Arrest in Diffuse Large B Cell Lymphoma (DLBCL) Cells and Sensitizes DLBCL Cells to Rituximab Therapy.

Induction of Apoptosis and Cell Cycle Arrest in Acute Myeloid Leukemia Cells by Histone Deacetylase Inhibitor, Suberoyl Hydroxamic Acid (SAHA): Lack of Cross-Resistance to Cytosine Arabinoside and Etoposide.

Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins

Rapamycin-induced G 1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin

Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cδ

Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides

Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only